Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Herbst

Showing results (41-50 of 395) with videos related to

Pageof 40
Sort By:
Clinical Laboratory Management Review : Official Publication of the Clinical Laboratory Management Association|August 6, 1995
Strategies for a successful organizational transition. Identifying staff roles and fulfilling their needs during changing timesD S Herbst, J E Dimmick
Current Oncology Reports|June 5, 2002
Angiogenesis inhibitors in lung cancerEdward S Kim, Roy S Herbst
Seminars in Oncology|August 9, 2003
The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancerRoy S Herbst, Michael S O'Reilly
Nature Medicine|August 13, 2021
Toward personalized treatment approaches for non-small-cell lung cancerMeina Wang, Roy S Herbst, Chris Boshoff
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2005
Angiogenesis and lung cancer: prognostic and therapeutic implicationsRoy S Herbst, Amir Onn, Alan Sandler
Clinical Lung Cancer|May 8, 2009
Multitargeted inhibitors in lung cancer: new clinical dataJair Bar, Roy S Herbst, Amir Onn
Geburtshilfe Und Frauenheilkunde|October 1, 1977
[Sterilization by partial resection of the oviducts via bipolar electrocoagulation (author's transl)]H A Hirsch, S Herbst, K Decker
Cancer Cell|June 6, 2022
When immunotherapy meets surgery in non-small cell lung cancerRoy S Herbst, Meina Wang, Lieping Chen
Hematology/Oncology Clinics of North America|December 4, 2016
Immunotherapy in Lung CancerLingling Du, Roy S Herbst, Daniel Morgensztern
Nature Reviews. Cancer|December 2, 2004
Gefitinib--a novel targeted approach to treating cancerRoy S Herbst, Masahiro Fukuoka, José Baselga
Pageof 40

Showing results (41-50 of 395) with videos related to

Sort By:
Pageof 40
Clinical Laboratory Management Review : Official Publication of the Clinical Laboratory Management Association|August 6, 1995
Strategies for a successful organizational transition. Identifying staff roles and fulfilling their needs during changing timesD S Herbst, J E Dimmick
Current Oncology Reports|June 5, 2002
Angiogenesis inhibitors in lung cancerEdward S Kim, Roy S Herbst
Seminars in Oncology|August 9, 2003
The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancerRoy S Herbst, Michael S O'Reilly
Nature Medicine|August 13, 2021
Toward personalized treatment approaches for non-small-cell lung cancerMeina Wang, Roy S Herbst, Chris Boshoff
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2005
Angiogenesis and lung cancer: prognostic and therapeutic implicationsRoy S Herbst, Amir Onn, Alan Sandler
Clinical Lung Cancer|May 8, 2009
Multitargeted inhibitors in lung cancer: new clinical dataJair Bar, Roy S Herbst, Amir Onn
Geburtshilfe Und Frauenheilkunde|October 1, 1977
[Sterilization by partial resection of the oviducts via bipolar electrocoagulation (author's transl)]H A Hirsch, S Herbst, K Decker
Cancer Cell|June 6, 2022
When immunotherapy meets surgery in non-small cell lung cancerRoy S Herbst, Meina Wang, Lieping Chen
Hematology/Oncology Clinics of North America|December 4, 2016
Immunotherapy in Lung CancerLingling Du, Roy S Herbst, Daniel Morgensztern
Nature Reviews. Cancer|December 2, 2004
Gefitinib--a novel targeted approach to treating cancerRoy S Herbst, Masahiro Fukuoka, José Baselga
Pageof 40